LONDON, Jan. 30, 2025 /PRNewswire/ -- LifeArc Ventures, which invests in innovative early-stage life science companies as part of LifeArc, today announced substantial progress in 2024, with three ...
TORONTO, Jan. 27, 2025 /CNW/ - Neuropeutics Inc announces a collaboration with LifeArc to develop a new small molecule for the treatment of motor neuron disease (MND), also known as Amyotrophic ...
TORONTO, Jan. 27, 2025 /CNW/ - Neuropeutics Inc announces a collaboration with LifeArc to develop a new small molecule for the treatment of motor neuron disease (MND), also known as Amyotrophic ...
An exciting opportunity has arisen to join a national research programme with the aim of speeding up the diagnosis and treatment of rare respiratory diseases. The LifeArc Centre for Rare Respiratory ...
About the Cystic Fibrosis Trust Cystic Fibrosis Trust is the only UK-wide charity dedicated to uniting for a life unlimited for everyone affected by cystic fibrosis. The Trust funds cutting edge ...
Self-funded, non-profit medical research organisation and charity LifeArc has announced today that it is to launch the Rare Disease Translational Challenge, which will invest over £100 million by ...
Like Bio-Hermes-001, the Bio-Hermes-002 study is paving the way for improving participation by trial participants who are traditionally underrepresented in Alzheimer’s clinical research, with an ...
Following the launch of LifeArc’s £100 million programme, Chronic Respiratory Infection Translational Challenge (CRI TC) – for the acceleration of the development of new clinical solutions to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback